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lowest for etanercept monotherapy ($22,487) and highest with
the combination of inﬂiximab and methotrexate ($24,807). For
monotherapy and combination therapy regimens, etanercept was
the least expensive option and most effective option compared to
other treatments, although differences in cost and effectiveness
across treatments were relatively small. After eliminating domi-
nated options, etanercept +MTX therapy increased the probabil-
ity of achieving an ACR 20 by 7% points and increased total
costs by $199 over etanercept monotherapy agent, resulting in an
incremental cost-effectiveness ratio of $2843 per additional
response. The incremental cost-effectiveness of combination
therapy compared to monotherapy was not markedly altered in
sensitivity analyses. CONCLUSION: Findings from this study
suggest that there are relatively small differences in cost and
effectiveness across biological response modiﬁers. Combination
therapy with biological response modiﬁers appears to provide an
increase in response compared to methotrexate alone, but at a
cost. Whether combination therapy can be considered cost-
effective depends on the value attached to achieving ACR
response.
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OBJECTIVE: Evaluate the cost-effectiveness of inﬂiximab com-
pared to adalimumab in early arthritis from an institutional
perspective. METHODS: To compare the cost and effectiveness,
a decision tree model was structured with a temporary horizon of
54 weeks. Only costs per drug were considered for this analysis,
as the rest of the costs are similar for institutional buyers.
Comparators: 3 mg/kg i.v. inﬂiximab + 15 mg oral metotrexate
(MTX) weekly. Inﬂiximab is administered at weeks 0, 2 and 6,
and every 8 weeks thereafter. Adalimumab subcutaneous injec-
tions of 40 mg every two weeks + 15 mg weekly of metotrexate
(oral). The effectiveness measures considered were the percentage
of patients achieving the ACR 50 and 70 response levels and
were obtained from international literature. Percentage of
patients achieving the ACR 50 and 70 levels with each treatment:
78% and 67% for inﬂiximab + metotrexate and 62% and 49%
respectively for the combination of adalimumab plus metotrex-
ate. Costs were estimated using prices of 2007 and are expressed
in United States dollars (exchange rate of 10.93 pesos/1 USD).
RESULTS: The expected annual treatment cost is $15,720.80
for inﬂiximab and $15,896.20 for adalimumab. The
cost-effectiveness ratios for ACR 50 and 70 per drug type are:
$20,154.80 and $23,463.90 respectively for inﬂiximab; and
$25,639 and $32,441.20 respectively for adalimumab. The
incremental cost-effectiveness ratio for inﬂiximab vs. adali-
mumab is -$1096.20 for ACR 50 and $974.40 for ACR 70. The
sensitivity analysis showed that these results are sensitive to drug
price variations. CONCLUSION: Inﬂiximab is a cost-effective
alternative compared to adalimumab for the treatment of early
arthritis from an institutional perspective in Mexico.
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OBJECTIVE: To evaluate from a Mexican public health
care institution perspective, the efﬁciency for using monthly
ibandronate for prevention of osteoporotic hip fractures in
Mexican women aged ﬁfty and older. METHODS: A hypotheti-
cal intervention to compare ibandrontate monthly versus alen-
dronate weekly to prevent osteoporotic hip fractures in
Mexican ﬁfty years and older women was modeled. The model
considers both efﬁcacy reported to each drug and the effective-
ness for their massive use based on the adherence to the therapy
reported. Taking into account both groups of women, those that
completed treatment and those that abandoned it, the model
estimates the total number of hip fractures possibly avoided for
each alternative and the investment required, only in terms of
direct cost. Considering that in Mexico there is not a deﬁned
cost-effectiveness threshold, the attention cost for hip fracture
was proposed like this. RESULTS: The attention cost for a hip
fracture in Mexico is reported at approximately USD$5100.
Although the model estimated a higher total direct cost for
using ibandronate (due to it’s higher rate of adherence) the
estimated ICER was USD$4734; this means the cost for addi-
tional hip fracture avoided comparing to alendronate. CON-
CLUSION: The use of monthly ibandronate to treat
osteoporosis and prevent osteoporotic hip fractures is a cost-
effective alternative. Although the public health care institutions
could be spending a maximum amount near to actual cost for
hip attention, it is possible to obtain additional savings if the
indirect costs of hip fractures and their associated deaths are
considered.
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OBJECTIVE: Long-term glucocorticoid use may lead to
glucocorticoid-induced osteoporosis and fractures which require
proper management. This study aims to aid decision-making on
preventive use of anti-resorptive agents for female long-term oral
glucocorticoid tablet users. METHODS: A retrospective analysis
of 1996–2004 Medical Expenditure Panel Survey data was con-
ducted to evaluate “actual use” outcomes. Direct medical costs
(in 2006 dollars) including selected adverse events related to
anti-resorptive agents were evaluated. Logistic analysis was per-
formed to estimate odds ratios of new fractures and osteoporosis
in treatment groups compared to the control group. Markov
modeling with second-order Monte Carlo simulations was
used to yield long-term estimates of these outcomes and address
parameter uncertainty. RESULTS: Of 1692 qualiﬁed female long-
term glucocorticoid users (representing 2.65% of the female
non-institutionalized U.S. population; average age = 49.8 years;
average prednisone-equivalent dose = 10.7 mg/day; average
therapy length = 215 days; white = 85.6%), 29.9% reported use
of any anti-resorptive agent; of those, 76.5% used hormone
replacement therapy (HRT) only, 12.1% used bisphosphonates
only, 2% used calcitonin only, 1.6% used raloxifene only and
7.8% used more than one anti-resorptive agent. Compared to
the controls, the estimated 10-year/lifetime incremental cost-
effectiveness ratios (ICERs; cost per fracture avoided) are $2,250/
$7,776 for HRT, $10,149/$28,078 for bisphosphonates,
$27,891/$46,102 for raloxifene and $60,862/$61,660 for calci-
tonin in hypothetical 50-year-old female glucocorticoid users. By
using the cost-effectiveness acceptability curve, different decision
makers may ﬁnd the corresponding range of probabilities that
remain cost-effective based on personalized willingness-to-pay.
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CONCLUSION: HRT is the most cost-effective option, followed
by bisphosphonates, for 50-year-old hypothetical females, but
some assumptions and limitations apply (including small sample
sizes for the calcitonin and raloxifene groups, and a likely selec-
tion bias in that bisphosphonate users are more likely to report
longer duration of glucocorticoid therapy). Because few guide-
lines included cost-effectiveness information, consideration of
these results may facilitate better management of glucocorticoid-
induced osteoporosis.
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OBJECTIVE: Abatacept is a new selective co-stimulation modu-
lator recently approved in Brazil for the treatment of patients
with moderately to severely active rheumatoid arthritis (RA) and
inadequate response to one or more disease-modifying anti-
rheumatic drugs (DMARDs). We estimated the cost-effectiveness
of Abatacept in patients with inadequate response to Methotr-
exate. METHODS: We developed a Markov simulation model to
depict progression of functional disability over time in patients
with moderately to severely active RA and inadequate response
to MTX. Functional disability was expressed in terms of the
Health Assessment Questionnaire Disability Index (HAQ-DI).
Patients were assumed to receive weekly pulse MTX alone or
weekly pulse MTX plus abatacept administered on days 1, 14,
and 29, and every 4 weeks thereafter. Costs with drug acquisi-
tion, administration and monitoring were considered. Estima-
tions used data from a Phase III clinical trial of abatacept in
patients with inadequate response to MTX (AIM) plus secondary
data sources. Cost-effectiveness of abatacept was expressed in
terms of the incremental cost (2006 Brazil R$) per quality-
adjusted life-year (QALY) gained versus MTX therapy alone;
lifetime horizons was employed in the analyses. Costs and health
effects were discounted at 3% annually. RESULTS: Over the
lifetime, abatacept therapy was estimated to yield an average of
1.61 additional QALYs per patient (vs. MTX alone) at a mean
incremental cost of R$146.095/QALY (US$83,483, US$1 =
R$1.75). CONCLUSION: Abatacept presented the best cost-
effectiveness ratio vis-à-vis etanercept, adalimumab, and
inﬂiximab, with its incremental costs of R$202.581/QALY,
R$189.100/QALY and R$236.479/QALY, respectively vs. Meth-
rotexate alone.
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OBJECTIVE: Rituximab is a monoclonal antibody with demon-
strated efﬁcacy (REFLEX trial) in rheumatoid arthritis patients
who responded inadequately to anti-TNF drugs (Cohen et al.
2006). The study assessed the total cost of rituximab therapy in
comparison with inﬂiximab, adalimumab, etanercept and abata-
cept under a private payer perspective in Brazil. A budget impact
analysis was performed. METHODS: This study assumed the
same efﬁcacy for all drugs, since there has not been any head-
to-head trial available until now, although indirect comparisons
show higher ACR response rates for rituximab. Direct annual
medical costs for biological drugs, IV administration, weekly
metotrexate (MTX) and routine exams were taken from a panel
of Brazilian rheumatologists. Base case dosages considered were:
rituximab (2 g every 8 months), abatacept (750 mg at weeks 0, 2,
4 and then every 4 weeks), inﬂiximab (4 mg/kg at weeks 0, 2, 6
and every 8 weeks), adalimumab (40 mg every other week) and
etanercept (50 mg every week). Local administration costs were
obtained from Scheinberg et al. 2005. Costs were reported in
2007 Brazilian Reais and discounted at a 5% rate in the BIA.
Therapies were evaluated using a 5-year horizon. In order to
assess uncertainty, one and two-way sensitivity analyses were
performed. RESULTS: In the base case scenario, rituximab
therapy resulted in a total annual cost of R$46,388 per patient.
Total annual costs per patient for the comparators were:
R$79,394 for inﬂiximab, R$90,831 for adalimumab, R$120,351
for etanercept and R$77,118 for abatacept. In the BIA, ritux-
imab therapy resulted in total savings of R$94,201,413 in 5 years
considering the population in the private health care system only.
Results were sensitive to dosage schedule (rituximab, inﬂiximab
and abatacept) and drug costs. CONCLUSION: Results of this
study suggest that therapy with rituximab is a dominant alterna-
tive for patients with rheumatoid arthritis in the Brazilian private
health care system.
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OBJECTIVE: To assess the direct and indirect economic conse-
quences of rheumatoid arthritis (RA) using real-world data.
METHODS: Medical Expenditure Panel Survey (MEPS) 2004
data was used to identify non-institutionalized U.S. persons with
RA. MEPS is a comprehensive survey of approximately 35,000
individuals consisting of detailed health care resource use expen-
ditures by payer, employment and income, insurance detail and
quality of life (QoL) information. These data are novel because
they are nationally representative, capture the elderly and their
expenditure better than managed care databases, and contain
direct and indirect costs and QoL measures in the same popula-
tion. Multiple linear and semi-log regressions were applied to
estimate the total annual health care expenditure and income
loss associated with RA. Covariates in expenditure equations
included demography, comorbidities and overall health status.
Semi-log regression for income rendered the distribution of
income symmetric. Covariates in the income equations included
demography, comorbidities, education, occupation and health
status. RESULTS: A total of 136 patients with RA were identiﬁed
in the data; 76% were women, and 56% were 41–64 years of
age. Total annual incremental expenditure associated with RA
was $4422 (P < 0.01) with adjusted R2 of 0.16 in the linear
regression and 0.41 in the semi-log regression. 14% of those
expenses were paid by the individual or their family, 28% by
Medicare, 39% by private insurance and 14% by Medicaid. As
expected, deterioration in overall health status increased health
care expenditures monotonically. In the income equation
(adjusted R2 = 0.39), persons with RA earned $3526 less annu-
ally (P = 0.03) than the mean income of $26,594 consistent with
the US Census Bureau, translating into a 13% decrease. Income
increased with education and with improved overall health
status. CONCLUSION: Even when controlling for other factors,
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